Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References On track to deliver operational efficiencies Savings of ~USD 1.5bn to be fully embedded by 2024 2022 Minimal impact, offsetting energy costs and inflation pressure in supply chain 23 Investor Relations | Q3 2022 Results ~USD 1.5bn 2023 2024 Integrated Operations unit synergies Simplification of M&S structure (non-customer-facing) Streamlining G&A functions. One-time restructuring cost estimated at 1 to 1.2x annual structural savings NOVARTIS | Reimagining Medicine

View entire presentation